ALFA Finder| Revenue growth | FY26 revenue dropped ~12% YoY due to industry-wide pricing erosion. |
|---|---|
| Margins | Gross margins recovering in Q4; merger expected to add 1-2% EBITDA. |
| Order book | Multiple orders for Exblifep in Europe; 4x Q-on-Q improvement. |
| Demand visibility | Stability seen in Q4; growth expected from non-regulated markets (Africa/Asia). |
| Management confidence | High on long-term anti-infective platform and Enmetazobactam lifetime value. |
Growth
FY26 revenue fell to ₹811cr from ₹922cr (FY25). Q4 revenue stable at ₹238cr YoY; EBITDA reached ₹42.3cr.
Outlook
Targeting 10-15% growth for FY27. ₹50cr capex for fill-finish/Cefiderocol facility. 7ACA project commissioning in Q1 2027.
Risks
Global antibiotic industry facing significant pricing/volume pressure, geopolitical instability, and supply chain cost volatility.
Earnings Call filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹877.00
- Market cap
- ₹5,252 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 605.9×Sector 43.8×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Board Meeting Date
Orchid Pharma Ltd intimated that its board will meet on November 14, 2026 to consider Q2 and half-year unaudited results. The trading window stays closed until 48 hours after results declaration.
Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.